After Biotech Dives Deeper Into Melanoma Data, It ‘Continues to Impress’

August 29, 2019

By The Life Science Report

Source: Streetwise Reports   08/27/2019

Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report.

In an Aug. 23 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported the highlights from Targovax ASA’s (TRVX:OSE) Q2/19 earnings conference call.

During the second quarter, Targovax posted an earnings per share of NOK0.72 compared to H.C. Wainwright’s estimate of NOK0.65. The biotech ended Q2/19 with NOK135 million in cash, which management said was enough runway through H1/20.


Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.




Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter






Pantginis also reported details about its clinical programs that management shared in the call. One topic was data from Targovax’s study of ONCOS-102 in melanoma patients who are both unresectable and refractory to anti-PD-1 therapies.

Initial results showed an overall response rate of 33% at six months. That included one complete response, two partial responses and one unconfirmed partial response. Also, despite individual responses, ONCOS-102 increased systemic and local immune activation, specifically “cytokine release and increased T cells tumor infiltration,” Pantginis noted. The oncolytic adenovirus also showed response specificity, i.e., tumor antigen specific T cells.

“We believe these data to be encouraging and to position ONCOS-102 well for the interim analysis set for H1/20,” commented Pantginis.

Also in the conference call, management reiterated that its mesothelioma program remains the next stock catalyst, with randomized Phase 2 data expected in January 2020. This event is made even more significant by the fact that the benchmark for mesothelioma is low, in other words reported overall survival with standard of care is six months, and few other possible, new therapeutics exist.

“We believe the data should be positive with ONCOS-102 supplying an additional layer of efficacy above the standard of care; if positive, we believe the shares could be poised for a relatively quick run to the NOK10 level,” Pantginis wrote.

H.C. Wainwright has a Buy rating and price target of NOK19 per share on Targovax, whose stock is currently trading at around NOK5.02 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from H. C. Wainwright, Targovax ASA, Earnings Update, August 23, 2019

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Joseph Pantginis, Ph.D., certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of Targovax ASA (including, without limitation, any option, right, warrant, future, long or short position).

As of July 31, 2019 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities Targovax ASA.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from Targovax ASA for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in Targovax ASA as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: TRVX:OSE,
)